SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Bladen Catherine L.) "

Sökning: WFRF:(Bladen Catherine L.)

  • Resultat 1-2 av 2
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Suñer, Silvia, et al. (författare)
  • Investigation of wear and wear Particles from a UHMWPE/multi-walled carbon nanotube nanocomposite for total joint replacements
  • 2014
  • Ingår i: Wear. - : Elsevier BV. - 0043-1648 .- 1873-2577. ; 317:1-2, s. 163-169
  • Tidskriftsartikel (refereegranskat)abstract
    • Ultra high molecular weight polyethylene (UHMWPE) has been extensively used as a bearing surface in joint prostheses. However, wear debris generated from this material has been associated with osteolysis and implant loosening. Alternative materials, such as polymer composites, have been investigated due to their exceptional mechanical properties. The goal of the present work was to investigate the wear rate, size and volume distributions, bioactivity and biocompatibility of the wear debris generated from a UHMWPE/Multi-walled carbon nanotube (MWCNT) nanocomposite material compared with conventional UHMWPE. The results showed that the addition of MWCNTs led to a significant reduction in wear rate. Specific biological activity and functional biological activity predictions showed that wear particles from the UHMWPE/MWCNT nanocomposite had a reduced osteolytic potential compared to those produced from the conventional polyethylene. In addition, clinically relevant UHMWPE/MWCNT wear particles did not show any adverse effects on the L929 fibroblast cell viability at any of the concentrations tested over time. These findings suggest that UHMWPE/MWCNT nanocomposites represent an attractive alternative for orthopaedic applications.
  •  
2.
  • Bladen, Catherine L., et al. (författare)
  • The TREAT-NMD Duchenne Muscular Dystrophy Registries : Conception, Design, and Utilization by Industry and Academia
  • 2013
  • Ingår i: Human Mutation. - : Hindawi Limited. - 1059-7794 .- 1098-1004. ; 34:11, s. 1449-1457
  • Tidskriftsartikel (refereegranskat)abstract
    • Duchenne muscular dystrophy (DMD) is an X-linked genetic disease, caused by the absence of the dystrophin protein. Although many novel therapies are under development for DMD, there is currently no cure and affected individuals are often confined to a wheelchair by their teens and die in their twenties/thirties. DMD is a rare disease (prevalence<5/10,000). Even the largest countries do not have enough affected patients to rigorously assess novel therapies, unravel genetic complexities, and determine patient outcomes. TREAT-NMD is a worldwide network for neuromuscular diseases that provides an infrastructure to support the delivery of promising new therapies for patients. The harmonized implementation of national and ultimately global patient registries has been central to the success of TREAT-NMD. For the DMD registries within TREAT-NMD, individual countries have chosen to collect patient information in the form of standardized patient registries to increase the overall patient population on which clinical outcomes and new technologies can be assessed. The registries comprise more than 13,500 patients from 31 different countries. Here, we describe how the TREAT-NMD national patient registries for DMD were established. We look at their continued growth and assess how successful they have been at fostering collaboration between academia, patient organizations, and industry.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-2 av 2

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy